



ISOLATION AND CHARACTERISATION OF NOVEL IMPURITY OF LANSOPRAZOLE FORMED IN 
THERMAL STRESS CONDITION 
 
SATYANARAYANA BATTU*, VASUDEV POTTABATHINI 
Department of Chemistry, University College of Science, Osmania University, Hyderabad 500007 
Email: satyambchem@yahoo.co.in  
Received: 03 Aug 2014 Revised and Accepted: 05 Sep 2014 
ABSTRACT 
Objective: The aim of the research work is to study the degradation of Lansoprazole in stress condition which is a proton pump inhibitor and 
controls the production of gastric acid in stomach. Thermal stress condition has been used to check the stability of the compound, in which one new 
degradation product was generated. 
Methods: The USP method for the identification of related compounds of Lansoprazole shows three known impurities N-Oxide impurity, Sulphone 
impurity and sulphide impurity. New degradation product formed in stress condition has been separated from the drug product and other known 
impurities by using Clarity Oligo RP column (250 mm x 4.6 mm, 5µ) and 10 mM Ammonium Acetate -Acetonitrile as a mobile phase. Same method 
has been scaled up on mass based preparative HPLC for the isolation of new degradation product.  
Results: The isolated impurity was structurally elucidated with 1H NMR, 13C NMR, HMBC, HSQC and HRMS. From the characterization studies it was 
found that novel impurity has 164.04 molecular weight with molecular formula C8H8N2S. The degradation product’s structure was matched with 2-
(Methylthio)-1H-benzo[d]imidazole per recorded analysis data. 
Conclusion: Isolated impurity was found to be novel and not reported in the literature. This method can be used for the degradation study of 
Lansoprazole and purification of novel impurity from drug and other degradation products 
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INTRODUCTION 
The identification and qualification of impurities or degradants in 
pharmaceuticals is critical in terms of product efficacy and drug 
safety. Regulatory bodies, such as the U. S. Food and Drug 
Administration (FDA), and the International Conference on 
Harmonization (ICH) have established clear and rigorous guidelines 
for setting thresholds for the reporting, identification, and 
qualification of impurities in drug substances and drug products. 
Stress testing is an important aspect of the drug development 
process. Appropriate stress testing can greatly assist the elucidation 
of forced degradation pathways. Recent efforts by the ICH with 
regard to stability and photo stability testing have brought increased 
regulatory scrutiny of impurities and the need to identify and qualify 
impurities at lower levels [1]. 
Controlling degradation-related impurities involves identifying 
which of the potential degradation products found during stress 
testing actually form in either the drug substance or product under 
long-term or accelerated storage conditions and then selecting the 
appropriate countermeasures to minimize the impurities or 
degradants. An impurity profiling study of forced degradation 
samples of Lansoprazole drug substance illustrates the 
identification process and its potential impact on pharmaceutical 
development [2]. Lansoprazole is a substituted benzimidazole, 
named as(RS)-2-({[3- methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-
yl]methyl}sulfinyl)-1H-benzimidazole. Its empirical formulais 
C16H14F3N3O2Swith a molecular weight of 369.36. Lansoprazole 
and its USP Impurities, Reported impurity and newly formed 
Thermal degradant impurities were shown in Fig.1. Lansoprazole 
is used to treat and prevent stomach intestinal ulcers, erosive 
esophagit is (damage to the esophagus from stomach acid), and 
other conditions involving excessive stomach acid such as 
Zollinger-Ellison syndrome [3]. 
In the literature, limited LC methods were reported for the 
determination of the assay and related substances of LAN. Some 
analytical assay methods were reported for the estimation of 
individual and combinations with other drugs in human plasma and 
dosage forms [4–12]. One chiral method and chemo metric approach 
by HPLC is available to separate known impurities of Lansoprazole, 
but has not proven the stability-indicating nature [13-14]. Some 
research work was done on the synthesis and characterisation of 
impurities formed during the forced degradation of LANS [15-16]. 
The present study is on impurities formed during the forced 
degradation under thermal stress conditions. 
 
 
Fig. 1: Chemical Structures of Lansoprazole and its USP 
Impurities, Reported impurity and newly formed Thermal 
degradant 
 
MATERIALS AND METHODS 
The investigated sample of lansoprazole and its USP impurities were 
procured from Nosch Labs Private Limited, India. Solvents and 
buffer used for analysis were HPLC grade acetonitrile and methanol 
(Rankem), Ammonium acetate (Fisher Scientific-Qualigens) and 
Water used was Milli-Q grade. 
Equipment 
Mass mediated high performance liquid chromatography 
A Mass mediated preparative HPLC equipped with waters pump module 
2545, UV detector module-2996 and mass detector module 3100, 
Sample manager module-2767, Mass lynx data handling system was 
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used. This system was equipped with both analytical port and 
preparative port. Mass capillary voltage was maintained 3 kv, Source 
temperature 150 0C and disolvation temperature 350 0C for the proper 
ionisation. 0.1 % formic acid is used in Water: Methanol (90:10) as a 
makeup solvent to the mass detector through splitter. 
Mass mediated analytical HPLC parameters 
Column: Clarity 5 µ Oligo RP (250 x 4.6) 
Mobile phase: 10 mM Ammonium Acetate (A): Acetonitrile (B) 
T/ % of B: 0.01/10, 5/10, 5.1/35, 25/35, 25.1/90, 30/90, 30.1/10, 
35/10 
Diluent: Mobile phase 
UV Detection: 285 nm 
HRMS (High Resolution Mass Spectrometry) 
Sample was analysed on the waters micro mass Q-TOF equipped 
with ESI ion source. Sample was analysed in positive mode. Caffeine 
(m/z: 194.080383 Da) was used as internal standard to calibrate the 
mass range and mass accuracy. Data was acquired in positive mode 
using Masslynx software. 
Nuclear magnetic resonance spectroscopy (1H&13C -NMR, HMBC, 
HSQC) 
The 1H and 13C NMR spectra of thermal degraded Impurity were 
recorded in DMSO-d6 at 400 MHz, Bruker 400MHz Advance NMR 
Spectrometer. The 1H and 13C chemical shifts are reported on δ scale 
in ppm, relative to TMS (δ 0.00 ppm) and DMSO-d6 (δ 39.50 ppm) as 
internal standards respectively. 
Thermal stress method 
Thermal degradation studies were carried out as per the guidelines 
of ICH. 100 mg of standard drug heated at 105 o C for 8 h to study 
thermal degradation. For analytical study thermally exposed sample 
was dissolved in methanol and diluted with mobile phase and 10 µl 
injected in to the system and the chromatograms were recorded to 
assess the stability of the sample. 
RESULTS AND DISCUSSION 
Identification of new thermal degradation product 
After thermal degradation the crude sample was injected into the 
analytical column for the separation of degradation products from 
the drug peak. To obtain the baseline separation different mobile 
phases has been used like ammonium formate, ammonium acetate, 
Trifluro acetic acid, formic acid and acetic acid. Various columns 
were screened to check the separation and symmetrical peak shape 
like YMC ODS, YMC Triart, Sunfire, X-terra, X-bridge, Agilent zorbax 
CN, Zorbax phenyl and Clarity Oligo. Finally desired separation was 
achieved using the 10 mM ammonium acetate and acetonitrile as a 
mobile phase and Clarity Oligo column (250 x 4.6 mm, 5µ). In the 
developed method, the chromatogram shows Peak-2 (RT 8.40, 
19.95%) as a novel degradant having different mass than reported 
impurities in the literature. Which indicates that peak-2 is a novel 
thermal degradant formed in this degradation procedure. The 
details of the degradation products retention time and molecular 
weights has been compiled in the in the below table-1. 
 
Table 1: Degradation products formed on Thermal stress condition 
S. No. Peak Label Retention time Area% Observed mass Exact mass About the peak 
1 Peak -1 6.45 12.02 149.15 (M-H) 150.20 Reported Impurity-A 
2 Peak-2 8.40 19.95 163.20 (M-H) 164.04 NovelThermal impurity-B 
3 Peak-3 16.62 24.33 368.29 (M-H) 369.08 Drug Lansoprazole 
4 Peak-4 24.85 22.48 352.30 (M-H) 353.08 USP Impurity-C 
 
 
Fig. 2: Standard chromatogram of Lansoprazole 
 
 
Fig. 3: Chromatogram of Lansoprazole after degradation 
 
Isolation of thermal degradation product 
This degradation study clearly indicates that the peak observed at 
8.40 min retention time and having mass m/z 163.20 (M-H) was 
new entity in thermal degradation and remaining peaks were 
matching with the already reported impurities. To separate this 
novel impurity formed in stressed thermal condition we scaled up 
the analytical method to preparative scale. Using the same mobile 
phase and column having dimension (250 x 19 mm, 5µ) and a flow 
rate 19 ml min-1degradation product has been isolated. In mass 
based preparative system splitter has been used after the column 
through which flow has been spiltted in the ratio 1000:1. The one 
part of the flow is passed through mass detector by diluting with 
make pump using 1 ml min-1 flow rate. For the proper ionisation of 
the desired impurity 0.1 % formic acid has been used as it is more 
volatile and enhances the ionisation. The delay time of the fraction 
collector has been investigated by using dye at same flow rate and 
the same parameters have been given as a input to get the good 
recovery. The crude sample was diluted with mobile phase and 
injected into the preparative column in three consecutive injections. 
The fractions have been collected on the basis of mass threshold 
parameters of total ion chromatogram. After completion of 
purification collected all fractions of mass 163.20 (M-H) pooled 
together and lyophilized to get free solid. 
Structure elucidation of thermal degradation product 
Compound m/z: 164.04 obtained from lyophilisation characterized 
by using HRMS, NMR (1H-NMR, 13 C NMR, HMBC and HSQC). 
High resolution mass spectrometry 
Sample was analysed on the waters micro mass q-TOF equipped 
with ESI ion source. Sample was analysed in positive mode. Caffeine 
(m/z: 194.080383 Da) was used as internal standard to calibrate the 
mass range and mass accuracy. Data was acquired in positive mode 
using Masslynx software. 
From the mass spectrum it was showing  
1. Monoisotopic mass with even electron ions (m/z: 
165.0463(M+H)) 
2. Elements observed: C: 0-8 H: 0-9 N: 0-2 S: 0-1 
3. Molecular Formula: C8 H9 N2 S (M+H) 
From information provided by HRMS report it is matching with 
expected structure of thermal degradant. 
 
 
Fig. 4: Mass elemental composition report of thermal 
degradant. 
 
Nuclear Magnetic Resonance (1H&13C -NMR, HMBC, HSQC): 
 
 
Table 2: NMR chemical shift values for Thermal degradation product 
Position 1 H 1HChemical shift in PPM 13C Chemical shift in PPM 
1 1H 7.7 112.971 
2 1H 7.5 125.052 
3 1H 7.5 125.052 
4 1H 7.7 112.971 
5 - - 132.489 
6 - - 132.489 
7 1H 10.6 - 
8 - - 152.689 
9 3H 2.9 14.4 
 
 
Fig. 5: 1H NMR spectrum of degradation product in DMSO 
 
Fig. 6: 1H NMR Spectrum of degradation product in DMSO+TFA 
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Fig. 7: 13C NMR Spectrum, Extra signals due to DMSO+TFA 
 
 
Fig. 8: HMBC data of degradation product 
 
Fig. 9: HSQC report of degradation product 
 
 
Fig. 10: Newly formed thermal degradation product purity 
chromatogram. 
From the above information obtained from the HRMS and NMR 
spectral data it is clearly matching the assumed structure of thermal 
degradation product. The newly formed thermal degradation 
product was separated in this developed method from its USP 
impurities and Lansoprazole. Chromatogram of Lansoprazole, USP 
impurities and newly formed thermal impurity were shown below. 
 
 
Fig. 11: Chromatogram of Lansoprazole, USP impurities and 
newly formed thermal impurity 
 
 




Fig. 13: Mass spectrum of USP N-Oxide impurity 
 
Table 3: HSQC& HMBC Correlations 
HSQC HMBC 
3H (2.9) 14.4 3H (2.9) 152.689 (Quaternary) 
2H (7.7) 112.971 2H (7.7) 125.052, 132.489 
2H (7.5) 125.052 2H (7.5) 112.971 
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Fig. 14: Mass spectrum of Lansoprazole 
 
 
Fig. 15: Mass spectrum of USP Sulphone impurity 
 
 
Fig. 16: Mass spectrum of USP Sulphide impurity 
 
CONCLUSION 
The fast, simple and sensitive method has been optimised for the 
separation of degradation product of Lansoprazole in thermally 
stressed condition. The thermal degraded impurity of Lansoprazole 
was identified and isolated using a mass mediated preparative HPLC 
system equipped analytical and preparative ports. Isolated 
degradant product was characterized by HRMS and NMR (1H, 13C and 
HMBC, HSQC) techniques. The HRMS and NMR spectral data of 
isolated product was confirmed to have a mass of 164.04 and with 
molecular formula of C8H8N2S. It was further confirmed that the 
isolated thermal impurity from this method is different from all the 
reported impurities of Lansoprazole in the literature, having 
chemical name of 2-(Methylthio)-1H-benzo[d] imidazole. 
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